Update on the pathogenesis of complex regional pain syndrome: Role of oxidative stress

Canadian Journal of Anesthesia

Volumn 59, Issue 9, 2012, Pages 875-881

  Taha, Rame ^a   Blaise, Gilbert A ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CORTICOSTEROID; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTINOCICEPTION; ANTIOXIDANT RESPONSIVE ELEMENT; AUTONOMIC DYSFUNCTION; BURNING SENSATION; CLINICAL FEATURE; COMPLEX REGIONAL PAIN SYNDROME; DISEASE COURSE; GENE INDUCTION; HUMAN; INFLAMMATORY PAIN; LIMB PAIN; MITOCHONDRION; MITOCHONDRION DYSFUNCTION; MOTOR DYSFUNCTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SENSORY DYSFUNCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTIOXIDANTS; COMPLEX REGIONAL PAIN SYNDROMES; DISEASE PROGRESSION; HUMANS; MITOCHONDRIA; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RESPONSE ELEMENTS; TIME FACTORS;

EID: 84867012427     PISSN: 0832610X     EISSN: 14968975     Source Type: Journal    
DOI: 10.1007/s12630-012-9748-y     Document Type: Review

References (59)

1. Sebastin SJ. Complex regional pain syndrome. Indian J Plast Surg 2011; 44: 298-307.
2. Bruehl S, Harden RN, Galer BS, et al. External validation of IASP diagnostic criteria for complex regional pain syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. Pain 1999; 81: 147-54.
3. Perez RS, Zollinger PE, Dijkstra PU, et al. Evidence based guidelines form complex regional pain syndrome type 1. BMC Neurol 2010; 10: 20.
4. Bruehl S. An update on the pathophysiology of complex regional pain syndrome. Anesthesiology 2010; 113: 713-25.
5. Maihofner C, Seifert F, Markovic K. Complex regional pain syndromes: new pathophysiological concepts and therapies. Eur J Neurol 2010; 17: 649-60.
6. Groeneweg G, Huygen FJ, Coderre TJ, Zijlstra FJ. Regulation of peripheral blood flow in complex regional pain syndrome: clinical implication for symptomatic relief and pain management. BMC Musculoskelet Disord 2009; 10: 116.
7. Bruehl S, Chung OY. How common is complex regional pain syndrome-type I? Pain 2007; 129: 1-2.
8. de Mos M, de Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH, Sturkenboom MC. The incidence of complex regional pain syndrome: a population-based study. Pain 2007; 129: 12-20.
9. Goebel A. Complex regional pain syndrome in adults. Rheumatology (Oxford) 2011; 50: 1739-50.
10. Lauder A, McCabe CS, Rodham K, Norris E. An exploration of the support person's perceptions and experiences of complex regional pain syndrome and the rehabilitation process. Musculoskeletal Care 2011; DOI: 10.1002/msc.211.
11. Fechir M, Geber C, Birklein F. Evolving understandings about complex regional pain syndrome and its treatment. Curr Pain Headache Rep 2008; 12: 186-91.
12. de Boer RD, Marinus J, van Hilten JJ, et al. Distribution of signs and symptoms of complex regional pain syndrome type I in patients meeting the diagnostic criteria of the International Association for the Study of Pain. Eur J Pain 2011; 15: 830.e1-8.
13. Hsu ES. Practical management of complex regional pain syndrome. Am J Ther 2009; 16: 147-54.
14. Toshniwal G, Sunder R, Thomas R, Dureja GP. Management of complex regional pain syndrome type I in upper extremityevaluation of continuous stellate ganglion block and continuous infraclavicular brachial plexus block: a pilot study. Pain Med 2012; 13: 96-106.
15. Goldberg ME, Domsky R, Scaringe D, et al. Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome. Pain Physician 2005; 8: 175-9.
16. Shrivastav M, Musley S. Spinal cord stimulation for complex regional pain syndrome. Conf Proc IEEE Eng Med Biol Soc 2009; 2009: 2033-6.
17. Lucchinetti E, Wacker J, Maurer C, et al. Helium breathing provides modest antiinflammatory, but no endothelial protection against ischemia-reperfusion injury in humans in vivo. Anesth Analg 2009; 109: 101-8.
18. van der Plas AA, Marinus J, Eldabe S, Buchser E, van Hilten JJ. The lack of efficacy of different infusion rates of intrathecal baclofen in complex regional pain syndrome: a randomized, double-blind, crossover study. Pain Med 2001; 12: 459-65.
19. Baron R, Fields HL, Janig W, Kitt C, Levine JD. National Institutes of Health Workshop: Reflex sympathetic dystrophy/ complex regional pain syndromes-state-of-the science. Anesth Analg 2002; 95: 1812-6.
20. Taha R, Blaise G. Is complex regional pain syndrome an inflammatory process? Theories and therapeutic implications. Can J Anesth 2007; 54: 249-53.
21. Ludwig J, Baron R. Complex regional pain syndrome: an inflammatory pain condition? Drug Discovery Today: Disease Mechanisms 2004; 1: 449-55.
22. de Rooij AM, de Mos M, Sturkenboom MC, Marinus J, van den Maagdenberg AM, van Hilten JJ. Familial occurrence of complex regional pain syndrome. Eur J Pain 2009; 13: 171-7.
23. Birklein F, Schmelz M, Schifter S, Weber M. The important role of neuropeptides in complex regional pain syndrome. Neurology 2001; 57: 2179-84.
24. Schinkel C, Gaertner A, Zaspel J, Zedler S, Faist E, Schuermann M. Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. Clin J Pain 2006; 22: 235-9.
25. Fischer SG, Zuurmond WW, Birklein F, Loer SA, Perez RS. Antiinflammatory treatment of complex regional pain syndrome. Pain 2010; 151: 251-6.
26. Kramer HH, Eberle T, Uceyler N, et al. TNF-a in CRPS and 'normal' trauma-significant differences between tissue and serum. Pain 2011; 152: 285-90.
27. Uceyler N, Eberle T, Rolke R, Birklein F, Sommer C. Differential expression patterns of cytokines in complex regional pain syndrome. Pain 2007; 132: 195-205.
28. Huygen FJ, Niehof S, Zijlstra FJ, van Hagen PM, van Daele PL. Successful treatment of CRPS 1 with anti-TNF. J Pain Symptom Manage 2004; 27: 101-3.
29. Pauwels EK, Erba PA, Kostkiewicz M. Antioxidants: a tale of two stories. Drug News Perspect 2007; 20: 579-85.
30. Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol 2001; 54: 176-86.
31. Babbs CF. Oxygen radicals in ulcerative colitis. Free Radic Biol Med 1992; 13: 169-81.
32. Grune T. Oxidants and antioxidative defense. Hum Exp Toxicol 2002; 21: 61-2.
33. Halliwell B. Antioxidants in human health and disease. Annu Rev Nutr 1996; 16: 33-50.
34. Eisenberg E, Shtahl S, Geller R, et al. Serum and salivary oxidative analysis in complex regional pain syndrome. Pain 2008; 138: 226-32.
35. Coderre TJ, Xanthos DN, Francis L, Bennett GJ. Chronic postischemia pain (CPIP): a novel animal model of complex regional pain syndrome-type I (CRPS-I; reflex sympathetic dystrophy) produced by prolonged hindpaw ischemia and reperfusion in the rat. Pain 2004; 112: 94-105.
36. Coderre TJ, Bennett GJ. Objectifying CRPS-I. Pain 2008; 138: 3-4.
37. Zollinger PE, Tuinebreijer WE, Breederveld RS, Kreis RW. Can vitamin C prevent complex regional pain syndrome in patients with wrist fractures? A randomized, controlled, multicenter doseresponse study. J Bone Joint Surg Am 2007; 89: 1424-31.
38. Besse JL, Gadeyne S, Galand-Desme S, Lerat JL, Moyen B. Effect of vitamin C on prevention of complex regional pain syndrome type I in foot and ankle surgery. Foot Ankle Surg 2009; 15: 179-82.
39. Shah AS, Verma MK, Jebson PJ. Use of oral vitamin C after fractures of the distal radius. J Hand Surg Am 2009; 34: 1736-8.
40. Dikalova AE, Bikineyeva AT, Budzyn K, et al. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res 2010; 107: 106-16.
41. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 2003; 15: 335-44.
42. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005; 39: 359-407.
43. Tan EC, Janssen AJ, Roestenberg P, van den Heuvel LP, Goris RJ, Rodenburg RJ. Mitochondrial dysfunction in muscle tissue of complex regional pain syndrome type I patients. Eur J Pain 2011; 15: 708-15.
44. Tan EC, Ter Laak HJ, Hopman MT, van Goor H, Goris RJ. Impaired oxygen utilization in skeletal muscle of CRPS I patients. J Surg Res 2012; 173: 145-52.
45. Smith RA, Porteous CM, Gane AM, Murphy MP. Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci USA 2003; 100: 5407-12.
46. Lee JM, Li J, Johnson DA, et al. Nrf2, a multi-organ protector? FASEB J 2005; 19: 1061-6.
47. Leonard MO, Kieran NE, Howell K, et al. Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury. FASEB J 2006; 20: 2624-6.
48. Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 2011; 85: 241-72.
49. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002; 62: 5196-203.
50. Rojo AI, Innamorato NG, Martín-Moreno AM, De Ceballos ML, Yamamoto M, Cuadrado A. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 2010; 58: 588-98.
51. Tkachev VO, Menshchikova EB, Zenkov NK. Mechanism of the Nrf2/Keap1/ARE signaling system. Biochemistry (Mosc) 2011; 76: 407-22.
52. Osburn WO, Wakabayashi N, Misra V, et al. Nrf2 regulates an adaptive response protecting against oxidative damage following diquat-mediated formation of superoxide anion. Arch Biochem Biophys 2006; 454: 7-15.
53. Thangasamy A, Rogge J, Krishnegowda NK, Freeman JW, Ammanamanchi S. Novel function of transcription factor Nrf2 as an inhibitor of RON tyrosine kinase receptor-mediated cancer cell invasion. J Biol Chem 2011; 286: 32115-22.
54. Feng Z, Liu Z, Li X, et al. a-Tocopherol is an effective phase II enzyme inducer: protective effects on acrolein-induced oxidative stress and mitochondrial dysfunction in human retinal pigment epithelial cells. J Nutr Biochem 2010; 21: 1222-31.
55. Osburn WO, Kensler TW. Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 2008; 659: 31-9.
56. de Mos M, Laferriere A, Millecamps M, J et al. Role of NFkappaB in an animal model of complex regional pain syndrome- type I (CRPS-I). J Pain 2009; 10: 1161-9.
57. Marzec JM, Christie JD, Reddy SP, et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J 2007; 21: 2237-46.
58. Arisawa T, Tahara T, Shibata T, et al. Nrf2 gene promoter polymorphism and gastric carcinogenesis. Hepatogastroenterology 2008; 55: 750-4.
59. Smith HS. The role of genomic oxidative-reductive balance as predictor of complex regional pain syndrome development: a novel theory. Pain Physician 2010; 13: 79-90.